Home >> General Pharmaceuticals >> Housing >> Food & Beverage >>

Galderma S.A. - Product Pipeline Review - 2015

Published: Feb-2015 | Format: PDF | Global Markets Direct | Number of pages: 33 | Code: MRS - 7044

 

Global Markets Direct’s, ‘Galderma S.A. Product Pipeline Review 2015’, provides an overview of the Galderma S.A.’s pharmaceutical research and development focus.

 

This report provides comprehensive information on the current therapeutic developmental pipeline of Galderma S.A.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

 

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

 

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

 

Scope

 

The report provides brief overview of Galderma S.A. including business description, key information and facts, and its locations and subsidiaries
The report reviews current pipeline of Galderma S.A.’s human therapeutic division and enlists all their major and minor projects
The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones 
Special feature on out-licensed and partnered product portfolio
The report summarizes all the dormant and discontinued pipeline projects
Latest company statement 
Latest news and deals relating to the Galderma S.A.’s pipeline products

 

Reasons to buy

 

Evaluate Galderma S.A.’s strategic position with total access to detailed information on its product pipeline
Assess the growth potential of Galderma S.A. in its therapy areas of focus
Identify new drug targets and therapeutic classes in the Galderma S.A.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
Develop strategic initiatives by understanding the focus areas of Galderma S.A. and exploit collaboration and partnership opportunities
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Plan mergers and acquisitions effectively by identifying the most promising pipeline of Galderma S.A.
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Explore the dormant and discontinued projects of Galderma S.A. and identify potential opportunities in those areas
Avoid Intellectual Property Rights related issues

Table of Contents
 

 

Table of Contents 2
List of Tables 4
List of Figures 4
Galderma S.A. Snapshot 5
Galderma S.A. Overview 5
Key Information 5
Key Facts 5
Galderma S.A. - Research and Development Overview 6
Key Therapeutic Areas 6
Galderma S.A. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Combination Treatment Modalities 10
Pipeline Products - Partnered Products 11
Partnered Products/Combination Treatment Modalities 12
Galderma S.A. - Pipeline Products Glance 13
Galderma S.A. - Late Stage Pipeline Products 13
Phase III Products/Combination Treatment Modalities 13
Galderma S.A. - Clinical Stage Pipeline Products 14
Phase II Products/Combination Treatment Modalities 14
Phase I Products/Combination Treatment Modalities 15
Galderma S.A. - Early Stage Pipeline Products 16
Discovery Products/Combination Treatment Modalities 16
Galderma S.A. - Unknown Stage Pipeline Products 17
Unknown Products/Combination Treatment Modalities 17
Galderma S.A. - Drug Profiles 18
(adapalene + benzoyl peroxide) 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
trifarotene 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
CD2475/101 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
resiquimod 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Galderma S.A. - Pipeline Analysis 22
Galderma S.A. - Pipeline Products by Target 22
Galderma S.A. - Pipeline Products by Route of Administration 23
Galderma S.A. - Pipeline Products by Molecule Type 24
Galderma S.A. - Pipeline Products by Mechanism of Action 25
Galderma S.A. - Recent Pipeline Updates 26
Galderma S.A. - Dormant Projects 27
Galderma S.A. - Company Statement 28
Galderma S.A. - Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29

 

Appendix 32
Methodology 32
Coverage 32
Secondary Research 32
Primary Research 32
Expert Panel Validation 32
Contact Us 32
Disclaimer 33


 

List of Tables
 

 

Galderma S.A., Key Information 5
Galderma S.A., Key Facts 5
Galderma S.A. - Pipeline by Indication, 2015 7
Galderma S.A. - Pipeline by Stage of Development, 2015 8
Galderma S.A. - Monotherapy Products in Pipeline, 2015 9
Galderma S.A. - Combination Treatment Modalities in Pipeline, 2015 10
Galderma S.A. - Partnered Products in Pipeline, 2015 11
Galderma S.A. - Partnered Products/ Combination Treatment Modalities, 2015 12
Galderma S.A. - Phase III, 2015 13
Galderma S.A. - Phase II, 2015 14
Galderma S.A. - Phase I, 2015 15
Galderma S.A. - Discovery, 2015 16
Galderma S.A. - Unknown, 2015 17
Galderma S.A. - Pipeline by Target, 2015 22
Galderma S.A. - Pipeline by Route of Administration, 2015 23
Galderma S.A. - Pipeline by Molecule Type, 2015 24
Galderma S.A. - Pipeline Products by Mechanism of Action, 2015 25
Galderma S.A. - Recent Pipeline Updates, 2015 26
Galderma S.A. - Dormant Developmental Projects,2015 27
Galderma S.A., Other Locations 29
Galderma S.A., Subsidiaries 30


List of Figures
 

Galderma S.A. - Pipeline by Top 10 Indication, 2015 7
Galderma S.A. - Pipeline by Stage of Development, 2015 8
Galderma S.A. - Monotherapy Products in Pipeline, 2015 9
Galderma S.A. - Partnered Products in Pipeline, 2015 11
Galderma S.A. - Pipeline by Top 10 Target, 2015 22
Galderma S.A. - Pipeline by Top 10 Route of Administration, 2015 23
Galderma S.A. - Pipeline by Top 10 Molecule Type, 2015 24
Galderma S.A. - Pipeline Products by Top 10 Mechanism of Action, 2015 25

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

Single User | $(USD)1500 View Pricing